Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China.
Cell Death Dis. 2018 Sep 20;9(10):961. doi: 10.1038/s41419-018-0982-2.
Helicobacter pylori has coexisted with humans for approximately 60,000 years and greater than 50% of the global population is infected with H. pylori. H. pylori was successfully cultured in vitro in 1983 and studies of H. pylori have achieved substantial advances over the last 35 years. Since then, H. pylori has been characterized as the primary pathogenic factor for chronic gastritis, peptic ulcer, and gastric malignancy. Numerous patients have received H. pylori eradication treatment, but only 1-2% of H. pylori-infected individuals ultimately develop gastric cancer. Recently, numerous epidemiological and basic experimental studies suggested a role for chronic H. pylori infection in protecting against inflammatory bowel disease (IBD) by inducing systematic immune tolerance and suppressing inflammatory responses. Here we summarize the current research progress on the association between H. pylori and IBD, and further describe the detailed molecular mechanism underlying H. pylori-induced dendritic cells (DCs) with the tolerogenic phenotype and immunosuppressive regulatory T cells (Tregs). Based on the potential protective role of H. pylori infection on IBD, we suggest that the interaction between H. pylori and the host is complicated, and H. pylori eradication treatment should be administered with caution, especially for children and young adults.
幽门螺杆菌（Helicobacter pylori）与人类共存了大约 6 万年，超过 50%的全球人口感染了幽门螺杆菌。1983 年成功在体外培养了幽门螺杆菌，在过去的 35 年中，对幽门螺杆菌的研究取得了实质性进展。此后，幽门螺杆菌被确定为慢性胃炎、消化性溃疡和胃癌的主要致病因素。许多患者接受了幽门螺杆菌根除治疗，但只有 1-2%的幽门螺杆菌感染者最终会发展为胃癌。最近，大量的流行病学和基础实验研究表明，慢性幽门螺杆菌感染通过诱导系统免疫耐受和抑制炎症反应，在预防炎症性肠病（IBD）方面发挥作用。在这里，我们总结了目前关于幽门螺杆菌与 IBD 之间关联的研究进展，并进一步描述了幽门螺杆菌诱导具有耐受表型和免疫抑制性调节性 T 细胞（Tregs）的树突状细胞（DCs）的详细分子机制。基于幽门螺杆菌感染对 IBD 的潜在保护作用，我们认为幽门螺杆菌与宿主之间的相互作用很复杂，应谨慎进行幽门螺杆菌根除治疗，特别是对儿童和青年人群。
